0001209191-23-004122.txt : 20230119
0001209191-23-004122.hdr.sgml : 20230119
20230119202836
ACCESSION NUMBER: 0001209191-23-004122
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230117
FILED AS OF DATE: 20230119
DATE AS OF CHANGE: 20230119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bergstrom Donald A
CENTRAL INDEX KEY: 0001709772
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39385
FILM NUMBER: 23538718
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Relay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001812364
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-370-8837
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-17
0
0001812364
Relay Therapeutics, Inc.
RLAY
0001709772
Bergstrom Donald A
C/O RELAY THERAPEUTICS, INC.
399 BINNEY STREET, 2ND FLOOR
CAMBRIDGE
MA
02139
0
1
0
0
President, R&D
Common Stock
2023-01-17
4
A
0
160390
0.00
A
246276
D
Stock Option (Right to Buy)
20.45
2023-01-17
4
A
0
160390
0.00
A
2033-01-16
Common Stock
160390
160390
D
Stock Option (Right to Buy)
20.45
2023-01-17
4
A
0
160390
0.00
A
2033-01-16
Common Stock
160390
160390
D
Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
Includes 232,849 shares underlying RSUs
The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date.
Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer.
/s/ Brian Adams, as Attorney-in-Fact
2023-01-19